Newland Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of chiral pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Its main products are L-p-hydroxyphenylglycine series products and p-toluenesulfonic acid. The company was founded on September 15, 2005 and is headquartered in Changge, China.